{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:58:26Z","timestamp":1784735906515,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40263-022-00912-6","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:06:53Z","timestamp":1648739213000},"page":"541-549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav\u00ae) in Sleep Disorders: A Profile of Its Use"],"prefix":"10.1007","volume":"36","author":[{"given":"Young-A","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"issue":"3","key":"912_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40675-020-00178-8","volume":"6","author":"B Akpa","year":"2020","unstructured":"Akpa B, Lee K. Update on novel medications to treat narcolepsy. Curr Sleep Med Rep. 2020;6(3):189\u201397.","journal-title":"Curr Sleep Med Rep."},{"issue":"1","key":"912_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-019-00689-1","volume":"34","author":"MJ Thorpy","year":"2020","unstructured":"Thorpy MJ. Recently approved and upcoming treatments for narcolepsy. CNS Drugs. 2020;34(1):9\u201327.","journal-title":"CNS Drugs"},{"issue":"1","key":"912_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s13311-020-00919-1","volume":"18","author":"LM Trotti","year":"2021","unstructured":"Trotti LM, Arnulf I. Idiopathic hypersomnia and other hypersomnia syndromes. Neurotherapeutics. 2021;18(1):20\u201331.","journal-title":"Neurotherapeutics"},{"issue":"9","key":"912_CR4","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.5664\/jcsm.9328","volume":"17","author":"K Maski","year":"2021","unstructured":"Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881\u201393.","journal-title":"J Clin Sleep Med"},{"issue":"9","key":"912_CR5","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1111\/ene.14888","volume":"28","author":"CLA Bassetti","year":"2021","unstructured":"Bassetti CLA, Kallweit U, Vignatelli L, et al. European guideline and expert statements on the management of narcolepsy in adults and children. Eur J Neurol. 2021;28(9):2815\u201330.","journal-title":"Eur J Neurol"},{"key":"912_CR6","unstructured":"Jazz Pharmaceuticals. Xyrem\u00ae (sodium oxybate) oral solution, CIII: US prescribing information. 2020. https:\/\/pp.jazzpharma.com\/pi\/xyrem.en.USPI.pdf. Accessed 9 Feb 2022."},{"issue":"4","key":"912_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2165\/00023210-200721040-00007","volume":"21","author":"DM Robinson","year":"2007","unstructured":"Robinson DM, Keating GM. Sodium oxybate: a review of its use in the management of narcolepsy. CNS Drugs. 2007;21(4):337\u201354.","journal-title":"CNS Drugs"},{"issue":"8","key":"912_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s40267-014-0140-6","volume":"30","author":"KA Lyseng-Williamson","year":"2014","unstructured":"Lyseng-Williamson KA. Sodium oxybate: a guide to its use in narcolepsy. Drugs Ther Perspect. 2014;30(8):282\u20139.","journal-title":"Drugs Ther Perspect."},{"key":"912_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.sleep.2020.09.017","volume":"75","author":"AY Avidan","year":"2020","unstructured":"Avidan AY, Kushida CA. The sodium in sodium oxybate: is there cause for concern? Sleep Med. 2020;75:497\u2013501.","journal-title":"Sleep Med"},{"key":"912_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17425255.2021.1843632","volume":"17","author":"G Junnarkar","year":"2021","unstructured":"Junnarkar G, Allphin C, Profant J, et al. Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia. Expert Opin Drug Discov. 2021;17:1\u201311.","journal-title":"Expert Opin Drug Discov"},{"key":"912_CR11","doi-asserted-by":"publisher","first-page":"101440","DOI":"10.1016\/j.smrv.2021.101440","volume":"58","author":"PJ Jennum","year":"2021","unstructured":"Jennum PJ, Plazzi G, Silvani A, et al. Cardiovascular disorders in narcolepsy: review of associations and determinants. Sleep Med Rev. 2021;58:101440.","journal-title":"Sleep Med Rev"},{"issue":"7","key":"912_CR12","doi-asserted-by":"publisher","first-page":"e0180634","DOI":"10.1371\/journal.pone.0180634","volume":"12","author":"G Perrin","year":"2017","unstructured":"Perrin G, Korb-Savoldelli V, Karras A, et al. Cardiovascular risk associated with high sodium-containing drugs: a systematic review. PLoS ONE. 2017;12(7):e0180634.","journal-title":"PLoS ONE"},{"key":"912_CR13","unstructured":"Junnarkar G, Allphin-Jazz C, Profant J, et al. Development of JZP-258, a low-sodium formulation of oxybate for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy [abstract no. 134]. In: Psych Congress 2020."},{"key":"912_CR14","unstructured":"Jazz Pharmaceuticals. Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) oral solution, CIII: US prescribing information. 2021. https:\/\/pp.jazzpharma.com\/pi\/xywav.en.USPI.pdf. Accessed 9 Feb 2022."},{"key":"912_CR15","unstructured":"Jazz Pharmaceuticals. US FDA grants Orphan Drug Exclusivity (ODE) for Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) oral solution for idiopathic hypersomnia in adults [media release]. 3 Jan 2022. https:\/\/investor.jazzpharma.com\/."},{"key":"912_CR16","unstructured":"Chen C, Parvataneni R, Chandler P. Pharmacokinetics of lower-sodium oxybate in a phase 3, placebo-controlled, double-blind, randomized withdrawal study in adult participants with idiopathic hypersomnia [abstract no. 39]. In: ASCP 2021 Annual Virtual Meeting. 2021."},{"key":"912_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cts.12818","volume":"14","author":"C Chen","year":"2021","unstructured":"Chen C, Jenkins J, Zomorodi K, et al. Pharmacokinetics, bioavailability, and bioequivalence of lower-sodium oxybate in healthy participants in two open-label, randomized, crossover studies. Clin Transl Sci. 2021;14:1\u201310.","journal-title":"Clin Transl Sci"},{"issue":"Suppl 1","key":"912_CR18","doi-asserted-by":"publisher","first-page":"A361","DOI":"10.1093\/sleep\/zsaa056.946","volume":"43","author":"Y Dauvilliers","year":"2020","unstructured":"Dauvilliers Y, Lammers GJ, Lecendreux M, et al. Effects of sodium dxybate (SXB) on body mass index (BMI) in pediatric patients with narcolepsy [abstract no 0950]. Sleep. 2020;43(Suppl 1):A361.","journal-title":"Sleep"},{"issue":"3","key":"912_CR19","doi-asserted-by":"publisher","first-page":"zsaa206","DOI":"10.1093\/sleep\/zsaa206","volume":"44","author":"RK Bogan","year":"2021","unstructured":"Bogan RK, Thorpy MJ, Dauvilliers Y, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021;44(3):zsaa206.","journal-title":"Sleep"},{"issue":"1","key":"912_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1474-4422(21)00368-9","volume":"21","author":"Y Dauvilliers","year":"2022","unstructured":"Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, et al. Efficacy and safety of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomized withdrawal study. Lancet Neurol. 2022;21(1):53\u201365.","journal-title":"Lancet Neurol"},{"issue":"7","key":"912_CR21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S2352-4642(18)30133-0","volume":"2","author":"G Plazzi","year":"2018","unstructured":"Plazzi G, Ruoff C, Lecendreux M, et al. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation. Lancet Child Adolesc Health. 2018;2(7):483\u201394.","journal-title":"Lancet Child Adolesc Health."},{"key":"912_CR22","doi-asserted-by":"crossref","unstructured":"Foldvary-Schaefer N, Bogan RK, Thorpy MJ, et al. Lower-sodium oxybate dose titration and transition from sodium oxybate in a placebo-controlled, double-blind, randomized withdrawal study in adult participants with narcolepsy with cataplexy [abstract no. 2163]. Neurology. 2021;96(15 Suppl).","DOI":"10.1212\/WNL.96.15_supplement.2163"},{"key":"912_CR23","doi-asserted-by":"crossref","unstructured":"Dauvilliers Y, Foldvary-Schaefer N, Bogan RK, et al. Cataplexy-free days in a phase 3, placebo-controlled, double-blind, randomized withdrawal study of lower-sodium oxybate in adults with narcolepsy with cataplexy [abstract no. 2065]. Neurology. 2021;96(15 Suppl).","DOI":"10.1212\/WNL.96.15_supplement.2065"},{"issue":"Suppl 1","key":"912_CR24","doi-asserted-by":"publisher","first-page":"A281","DOI":"10.1093\/sleep\/zsaa056.736","volume":"43","author":"N Foldvary-Schaefer","year":"2020","unstructured":"Foldvary-Schaefer N, Thorpy MJ, Dauvilliers Y, et al. Quality of life in phase 3, placebo-controlled, double-blind, randomized withdrawal study of JZP-258 in adults with narcolepsy with cataplexy [abstract no 0740]. Sleep. 2020;43(Suppl 1):A281\u20132.","journal-title":"Sleep"},{"issue":"Suppl 2","key":"912_CR25","doi-asserted-by":"publisher","first-page":"A191","DOI":"10.1093\/sleep\/zsab072.484","volume":"44","author":"I Arnulf","year":"2021","unstructured":"Arnulf I, Morse AM, Chandler P, et al. Efficacy and safety of once- and twice-nightly dosing of lower-sodium oxybate in adults with idiopathic hypersomnia [abstract no 485]. Sleep. 2021;44(Suppl 2):A191\u20132.","journal-title":"Sleep"},{"issue":"15","key":"912_CR26","doi-asserted-by":"publisher","first-page":"e1754","DOI":"10.1212\/WNL.0000000000007264","volume":"92","author":"Y Dauvilliers","year":"2019","unstructured":"Dauvilliers Y, Evangelista E, Barateau L, et al. Measurement of symptoms in idiopathic hypersomnia: the idiopathic hypersomnia severity scale. Neurology. 2019;92(15):e1754\u201362.","journal-title":"Neurology"},{"key":"912_CR27","doi-asserted-by":"crossref","unstructured":"Morse AM, Chen A, Steininger T, et al. Effects of lower-sodium oxybate on 24-hour total sleep time: data from a phase 3 clinical study in adults with idiopathic hypersomnia [abstract no. 119]. In: World sleep congress. 2022.","DOI":"10.1212\/WNL.0000000000203244"},{"key":"912_CR28","unstructured":"Bogan R, Arnulf I, Thorpy M, et al. Long-term efficacy and safety of lower-sodium oxybate in a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia [abstract no. 11]. In: Psych Congress. 2021."},{"key":"912_CR29","unstructured":"Bogan R, Arnulf I, Thorpy M, et al. Long-term effects of lower-sodium oxybate on functioning and work productivity in participants with idiopathic hypersomnia [abstract no. 12]. In: Psych Congress. 2021."},{"issue":"Suppl 2","key":"912_CR30","first-page":"A192","volume":"44","author":"R Bogan","year":"2021","unstructured":"Bogan R, Foldvary-Schaefer N, Skowronski R, et al. Timing and duration of adverse events in a clinical trial of lower-sodium oxybate in participants with narcolepsy with cataplexy [abstract no 486]. Sleep. 2021;44(Suppl 2):A192.","journal-title":"Sleep"},{"issue":"Suppl 2","key":"912_CR31","doi-asserted-by":"publisher","first-page":"A195","DOI":"10.1093\/sleep\/zsab072.493","volume":"44","author":"Y Dauvilliers","year":"2021","unstructured":"Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, et al. Placebo-controlled, double-blind, randomized withdrawal study of lower-sodium oxybate in adults with idiopathic hypersomnia. Sleep. 2021;44(Suppl 2):A195.","journal-title":"Sleep"},{"issue":"1","key":"912_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1474-4422(21)00419-1","volume":"21","author":"LM Trotti","year":"2022","unstructured":"Trotti LM. Idiopathic hypersomnia: does first to approval mean first-line treatment? Lancet Neurol. 2022;21(1):25\u20136.","journal-title":"Lancet Neurol"}],"updated-by":[{"DOI":"10.1007\/s40263-022-00919-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00912-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T10:47:05Z","timestamp":1726915625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00912-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["912"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00912-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40263-022-00919-z","asserted-by":"object"}]},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"assertion":[{"value":"8 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40263-022-00919-z","URL":"https:\/\/doi.org\/10.1007\/s40263-022-00919-z","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Young-A Heo is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}